stockrowHims & Hers Health, Inc.
HIMS Healthcare Drug Manufacturers Specialty & Generic
Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.
- Revenue
- +38.3%
- EPS
- −294.7%
- Free cash flow
- +5.09%
- Total debt
- +40.8%
Quarter to June 2026, against a year earlier
Follow HIMS
Alert me
Hims & Hers Health, Inc. (HIMS) EPS (diluted)
Hims & Hers Health, Inc.'s EPS (diluted) for fiscal 2025 was $0.51, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was −$0.63. Over the past ten years it has ranged from −$2.07 (fiscal 2019) to $0.53 (fiscal 2024); the current reading is higher than 86% of that period. Hims & Hers Health, Inc. ranks 44th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.51 | (3.77%) |
| FY2024 | $0.53 | — |
| FY2023 | −$0.11 | — |
| FY2022 | −$0.32 | — |
| FY2021 | −$0.58 | — |
| FY2020 | −$0.51 | — |
| FY2019 | −$2.07 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.37 | — |
| Mar 2026 | −$0.40 | — |
| Dec 2025 | $0.08 | 33.33% |
| Sep 2025 | $0.06 | (64.71%) |
| 25 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LNTH Lantheus Holdings, Inc. compare | $4.06 |
| SUPN Indivior Pharmaceuticals Inc. compare | $3.58 |
| LQDA Liquidia Corporation compare | $1.37 |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $1.30 |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $0.52 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.33 |
| ALKS Alkermes plc compare | −$0.01 |
| HIMS Hims & Hers Health, Inc. | −$0.63 |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$1.43 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on HIMS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement